Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial
| Autor: | Antoine Thiery-Vuillemin, Fred Saad, Andrew J. Armstrong, Mototsugu Oya, Karina Costa Maia Vianna, Mustafa Özgüroğlu, Craig Gedye, Gary L Buchschacher, Ji Youl Lee, Urban Emmenegger, Jiri Navratil, Juan Antonio Virizuela, Anibal Salazar, Denis Maillet, Hiroji Uemura, Jeri Kim, Edit Lukacs, Laura Barker, Arnold N Degboe, Noel W. Clarke |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 40:5019-5019 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 5019 Background: The Phase III PROpel (NCT03732820) trial demonstrated at interim analysis a statistically significant clinical benefit from combining ola + abi in the first-line (1L) mCRPC setting vs placebo (pbo) + abi. Benefit was seen irrespective of a pt’s homologous recombination repair mutation (HRRm) status; median radiographic progression-free survival (rPFS) 24.8 for ola + abi vs 16.6 months for pbo + abi (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.54–0.81; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|